Penn Center for Myeloproliferative Neoplasms
Saar I Gill
Saar I Gill
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine
Graduate Group Affiliations
Contact information
Room 8-101
Smilow Translational Research Center
3400 Civic Center Blvd
Philadelphia, PA 19104
Smilow Translational Research Center
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: (215) 573-4015
Lab: (215) 573-4015
Lab: (215) 573-4015
Education:
MBBS (medicine)
University of Melbourne, 1999.
PhD (immunology)
University of Melbourne, 2011.
Permanent linkMBBS (medicine)
University of Melbourne, 1999.
PhD (immunology)
University of Melbourne, 2011.
Description of Clinical Expertise
Blood and Marrow TransplantationLeukemia
Myelodysplastic Syndromes
Myeloproliferative Neoplasms
Lymphoproliferative Neoplasms
Bone Marrow Failure
Description of Research Expertise
Tumor ImmunologyChimeric Antigen Receptor T cells
Mouse Models of Human Leukemia
Murine Xenografts
Adoptive Cellular Therapy
Genetic Engineering of T cells
Flow Cytometry
Selected Publications
Bhagwat AS, Torres L, Shestova O, Shestov M, Mellors PW, Fisher HR, Farooki SN, Frost BF, Loken MR, Gaymon AL, Frazee D, Rogal W, Frey N, Hexner EO, Luger SM, Loren AW, Martin ME, McCurdy SR, Perl AE, Stadtmauer EA, Brogdon JL, Fraietta JA, Hwang WT, Siegel DL, Plesa G, Aplenc R, Porter DL, June CH, Gill SI.: Cytokine-mediated CAR T therapy resistance in AML. Nature Medicine 30(12): 3697-3708. Dec 2024.Wellhausen N, Gill S.: CD45 threads the needle of cytokine cancer immunotherapy. Nature Immunology 25(10): 1774-1777, Oct 2024 Notes: DOI: 10.1038/s41590-024-01956-0
Kang Y, Lefebvre B, Pamies IM, Gill SI, Doucette AG, Denduluri S, Smith AM, McCurdy S, Luger S, Carver J, Scherrer-Crosbie M.: Symptomatic Heart Failure and Clonal Hematopoiesis-Related Mutations in Patients With Acute Myeloid Leukemia. Am Journal of Cardiology Page: 1:226:9-17. doi: 10.1016/j.amjcard.2024.06.033. Sep 2024.
Wellhausen N, Baek J, Gill SI, June CH.: Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance. Nature Reviews Cancer 24(9): 614-628. Sep 2024 Notes: DOI: 10.1038/s41568-024-00723-5
Chang JF, Wellhausen N, Engel NW, Landmann JH, Hopkins CR, Salas-McKee J, Bear AS, Selli ME, Agarwal S, Jadlowsky JK, Linette GP, Gill S, June CH, Fraietta JA, Singh N.: Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors. Cancer Immunology Research 12(9): 1136-1146. Sep 2024 Notes: DOI: 10.1158/2326-6066.CIR-24-0251
Vinnakota JM, Biavasco F, Schwabenland M, Chhatbar C, Adams RC, Erny D, Duquesne S, El Khawanky N, Schmidt D, Fetsch V, Zähringer A, Salié H, Athanassopoulos D, Braun LM, Javorniczky NR, Ho JNHG, Kierdorf K, Marks R, Wäsch R, Simonetta F, Andrieux G, Pfeifer D, Monaco G, Capitini C, Fry TJ, Blank T, Blazar BR, Wagner E, Theobald M, Sommer C, Stelljes M, Reicherts C, Jeibmann A, Schittenhelm J, Monoranu CM, Rosenwald A, Kortüm M, Rasche L, Einsele H, Meyer PT, Brumberg J, Völkl S, Mackensen A, Coras R, von Bergwelt-Baildon M, Albert NL, Bartos LM, Brendel M, Holzgreve A, Mack M, Boerries M, Mackall CL, Duyster J, Henneke P, Priller J, Köhler N, Strübing F, Bengsch B, Ruella M, Subklewe M, von Baumgarten L, Gill S, Prinz M, Zeiser R.: Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome. Nature Cancer 5(8): 1227-1249. Aug 2024.
Gardner RA, White C, Elsallab M, Farnia S, Fraint E, Grilley B, Bateman-House A, Grupp SA, Kenderian S, Locke FL, Nikiforow S, Oluwole OO, Rouce RH, Spiegel J, Shah NN, Sharma A, Komanduri K, Gill S.: ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies. Transplantation and Cell Therapy 30(8): 776-787, Aug 2024.
Connor MP, Prathapa N, Frey NV, Gill SI, Hexner EO, Bruno XJ, Lai CE, Loren AW, Luger SM, Matthews AH, McCurdy SR, Perl AE, Porter DL, Zeringue A, Oved JH, Olson TS, Pratz KW, Babushok DV.: Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia. Haematologica 109(8): 2732-2737. Aug 2024.
Veliz K, Shen F, Shestova O, Shestov M, Shestov A, Sleiman S, Hansen T, O'Connor RS, Gill S.: Deletion of CD38 enhances CD19 chimeric antigen receptor T cell function. Molecular Therapy Oncology 32(2): 200819. May 2024.
Sung AD, Koll T, Gier SH, Racioppi A, White G, Lew M, Free M, Agarwal P, Bohannon LM, Johnson EJ, Selvan B, Babushok DV, Frey NV, Gill SI, Hexner EO, Martin M, Perl AE, Pratz KW, Luger SM, Chao NJ, Fisher AL, Stadtmauer EA, Porter DL, Loren AW, Bhatt VR, Gimotty PA, McCurdy SR.: Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients. Transplantation and Cell Therapy 30(4): 415.e1-415.e16. Apr 2024.